Jane Street’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-32,147
| Closed | -$661K | – | 11855 |
|
|
2026
Q1 | $617K | Sell |
32,147
-10,775
| -25% | -$214K | ﹤0.01% | 7548 |
|
|
2025
Q4 | $709K | Sell |
42,922
-181,981
| -81% | -$3.07M | ﹤0.01% | 6931 |
|
|
2025
Q3 | $3.27M | Buy |
224,903
+139,571
| +164% | +$2.01M | ﹤0.01% | 4082 |
|
|
2025
Q2 | $1.19M | Sell |
85,332
-128,341
| -60% | -$1.81M | ﹤0.01% | 5286 |
|
|
2025
Q1 | $2.9M | Sell |
213,673
-15,492
| -7% | -$297K | ﹤0.01% | 3763 |
|
|
2024
Q4 | $4.67M | Sell |
229,165
-140,506
| -38% | -$3.6M | ﹤0.01% | 2754 |
|
|
2024
Q3 | $10.8M | Buy |
369,671
+138,307
| +60% | +$3.43M | ﹤0.01% | 1832 |
|
|
2024
Q2 | $5.37M | Buy |
231,364
+182,648
| +375% | +$3.51M | ﹤0.01% | 2870 |
|
|
2024
Q1 | $1,000K | Sell |
48,716
-100,249
| -67% | -$1.88M | ﹤0.01% | 5414 |
|
|
2023
Q4 | $3.2M | Buy |
148,965
+110,226
| +285% | +$2.18M | ﹤0.01% | 3545 |
|
|
2023
Q3 | $799K | Sell |
38,739
-34,061
| -47% | -$864K | ﹤0.01% | 5526 |
|
|
2023
Q2 | $2.15M | Sell |
72,800
-43,005
| -37% | -$1.21M | ﹤0.01% | 4067 |
|
|
2023
Q1 | $2.67M | Buy |
115,805
+100,836
| +674% | +$2.78M | ﹤0.01% | 3343 |
|
|
2022
Q4 | $416K | Buy |
+14,969
| New | +$445K | ﹤0.01% | 6456 |
|
|
2022
Q3 | – | Sell |
-13,923
| Closed | -$410K | – | 9832 |
|
|
2022
Q2 | $410K | Buy |
+13,923
| New | +$365K | ﹤0.01% | 7085 |
|
|
2022
Q1 | – | Sell |
-24,456
| Closed | -$1.09M | – | 10422 |
|
|
2021
Q4 | $1.09M | Buy |
24,456
+5,759
| +31% | +$273K | ﹤0.01% | 5713 |
|
|
2021
Q3 | $943K | Buy |
18,697
+14,384
| +334% | +$811K | ﹤0.01% | 6026 |
|
|
2021
Q2 | $338K | Sell |
4,313
-8,668
| -67% | -$536K | ﹤0.01% | 7941 |
|
|
2021
Q1 | $741K | Sell |
12,981
-19,613
| -60% | -$1.31M | ﹤0.01% | 6050 |
|
|
2020
Q4 | $2.73M | Buy |
32,594
+2,748
| +9% | +$166K | ﹤0.01% | 2951 |
|
|
2020
Q3 | $1.07M | Buy |
29,846
+6,919
| +30% | +$208K | ﹤0.01% | 3994 |
|
|
2020
Q2 | $554K | Sell |
22,927
-16,039
| -41% | -$377K | ﹤0.01% | 4921 |
|
|
2020
Q1 | $683K | Buy |
+38,966
| New | +$813K | ﹤0.01% | 3286 |
|
|
2019
Q4 | – | Sell |
-12,976
| Closed | -$199K | – | 5160 |
|
|
2019
Q3 | $199K | Buy |
+12,976
| New | +$248K | ﹤0.01% | 4652 |
|
|
2018
Q4 | – | Sell |
-10,020
| Closed | -$218K | – | 5077 |
|
|
2018
Q3 | $218K | Buy |
+10,020
| New | +$166K | ﹤0.01% | 4590 |
|
Other funds holding DNLI
Jane Street's DNLI Position: Q2 2026 in Review
Jane Street sold out of Denali Therapeutics (DNLI) in Q2 2026, closing a stake of 32,147 shares — an estimated $661K sold.
Jane Street first reported a position in DNLI in Q3 2018 and held it in 25 quarters. The position peaked at $10.8M in Q3 2024. 294 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.
- Jane Street reported no remaining Denali Therapeutics position as of Q2 2026 after selling out during the quarter.
- Jane Street sold 32,147 Denali Therapeutics shares in Q2 2026, an estimated $661K.
- Jane Street first reported a position in Denali Therapeutics in Q3 2018 and held it in 25 quarters.
- Jane Street's Denali Therapeutics position peaked at $10.8M in Q3 2024.
- 294 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.
Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.